Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond.

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease with rising incidence.
• Current guidelines advocate for objective treatment targets and steroid-sparing therapies.
• Effective management of UC requires understanding diverse therapeutic options.

Purpose of the Study:

• To review safety and efficacy data of current ulcerative colitis therapies.
• To summarize comparative effectiveness studies of available UC treatments.
• To guide rational treatment decisions for ulcerative colitis patients.

Main Methods:

• Review of recent regulatory approvals for biologic and small molecule agents.
• Analysis of randomized controlled trials and real-world data.
• Inclusion of network meta-analyses for comparative effectiveness.

Main Results:

• Several new therapeutic classes are approved for UC, including integrin antagonists, IL-12/23 antagonists, JAK inhibitors, and S1P receptor antagonists.
• Extensive data from RCTs, real-world studies, and meta-analyses inform comparative safety and efficacy.
• Numerous agents are now available for UC treatment, expanding clinical options.

Conclusions:

• The availability of diverse UC therapies necessitates careful consideration of individual patient factors.
• Evidence-based reviews are crucial for clinicians to position new therapies effectively.
• Shared decision-making between patients and clinicians is essential for optimal ulcerative colitis management.